Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lorantis Ltd.

This article was originally published in Start Up

Executive Summary

Existing drugs for immune-related conditions, such as Novartis AG's cyclosporin, tend to either suppress the system altogether (often with considerable side effects), or, like anti-inflammatory or broncho-dilatory products for asthma, treat the symptoms of the disease. This is because scientists have to date understood little of the workings of immune system tolerance, or indeed of immune system regulation more generally. The founding scientists of Lorantis Ltd. hope to have made some progress in this area. They have discovered the molecular mechanism underlying antigen-specific tolerance in animal models, potentially paving the way for a new generation of therapies that treat the causes of various immune-related diseases, rather than their symptoms.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts